pharma · Squamous Cell Carcinoma of Head and Neck · Breast Cancer · TVRD
Tvardi Therapeutics
Tvardi Therapeutics is a pharma organization headquartered in Houston, USA. It trades on NYSE under ticker TVRD. Primary therapeutic focus areas include Squamous Cell Carcinoma of Head and Neck, Breast Cancer, Head and N
Houston, USA HQ
2017 Founded
20 Employees
Public company Type
TVRD · NYSE Ticker
Company details
- Status
- Public
- HQ
- Houston, USA
- Founded
- 2017
- Employees
- 20
- Programs
- 6
- Drugs
- 2
- Patents
- 6
TTI-101
Phase 2 · small molecule · Head and Neck Squamous Cell Carcinoma
TTI-101 for Head and Neck Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at Tvardi Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code 2022-0625
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Tvardi Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Head and Neck Squamous Cell Carcinoma
- Status
- terminated
- Trials
- 1